169 related articles for article (PubMed ID: 35514789)
1. Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.
Carrieri P; Carrat F; Di Beo V; Bourlière M; Barré T; De Ledinghen V; Pageaux GP; Bureau M; Cagnot C; Dorival C; Delarocque-Astagneau E; Marcellin F; Pol S; Fontaine H; Protopopescu C;
JHEP Rep; 2022 Jun; 4(6):100481. PubMed ID: 35514789
[TBL] [Abstract][Full Text] [Related]
2. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
[TBL] [Abstract][Full Text] [Related]
3. Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort).
Barré T; Fontaine H; Ramier C; Di Beo V; Pol S; Carrieri P; Marcellin F; Cagnot C; Dorival C; Zucman-Rossi J; Zoulim F; Carrat F; Protopopescu C
Clin Nutr; 2022 Mar; 41(3):610-619. PubMed ID: 35124468
[TBL] [Abstract][Full Text] [Related]
4. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH).
Marcellin F; Brégigeon-Ronot S; Ramier C; Protopopescu C; Gilbert C; Di Beo V; Duvivier C; Bureau-Stoltmann M; Rosenthal E; Wittkop L; Salmon-Céron D; Carrieri P; Sogni P; Barré T; ; ; ; ;
JHEP Rep; 2023 Jan; 5(1):100614. PubMed ID: 36466990
[TBL] [Abstract][Full Text] [Related]
5. Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.
Wu HC; Jeng WJ; Pan MH; Hsieh YC; Lu SN; Chen CJ; Yang HI
JHEP Rep; 2022 Feb; 4(2):100410. PubMed ID: 35079699
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
8. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
10. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
[TBL] [Abstract][Full Text] [Related]
11. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).
Santos M; Protopopescu C; Delarocque-Astagneau E; Bourlière M; Petrov-Sanchez V; Di Beo V; Larrey D; Baudoin M; Dorival C; Bureau M; Fontaine H; Carrat F; Marcellin F; Pol S; Carrieri P;
Liver Int; 2022 Jan; 42(1):38-49. PubMed ID: 34520614
[TBL] [Abstract][Full Text] [Related]
12. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.
Barré T; Carrat F; Ramier C; Fontaine H; Di Beo V; Bureau M; Dorival C; Larrey D; Delarocque-Astagneau E; Mathurin P; Marcellin F; Petrov-Sanchez V; Cagnot C; Carrieri P; Pol S; Protopopescu C;
J Cannabis Res; 2022 Jun; 4(1):31. PubMed ID: 35690798
[TBL] [Abstract][Full Text] [Related]
13. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
14. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
[TBL] [Abstract][Full Text] [Related]
15. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
[TBL] [Abstract][Full Text] [Related]
16. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S
J Hepatol; 2016 Oct; 65(4):727-733. PubMed ID: 27349488
[TBL] [Abstract][Full Text] [Related]
17. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
18. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
Barré T; Nishimwe ML; Protopopescu C; Marcellin F; Carrat F; Dorival C; Delarocque-Astagneau E; Larrey D; Bourlière M; Petrov-Sanchez V; Simony M; Pol S; Fontaine H; Carrieri P;
J Viral Hepat; 2020 Dec; 27(12):1473-1483. PubMed ID: 32810343
[TBL] [Abstract][Full Text] [Related]
19. Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort).
Yaya I; Marcellin F; Costa M; Morlat P; Protopopescu C; Pialoux G; Santos ME; Wittkop L; Esterle L; Gervais A; Sogni P; Salmon-Ceron D; Carrieri MP;
Nutrients; 2018 May; 10(6):. PubMed ID: 29857547
[TBL] [Abstract][Full Text] [Related]
20. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
Poynard T; Lacombe JM; Deckmyn O; Peta V; Akhavan S; de Ledinghen V; Zoulim F; Samuel D; Mathurin P; Ratziu V; Thabut D; Housset C; Fontaine H; Pol S; Carrat F
JHEP Rep; 2021 Aug; 3(4):100298. PubMed ID: 34142073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
